Actively Recruiting
Germline Testing for Predisposition to Myeloid Malignancies
Led by Christopher Reilly · Updated on 2026-04-24
200
Participants Needed
1
Research Sites
385 weeks
Total Duration
On this page
Sponsors
C
Christopher Reilly
Lead Sponsor
B
Broad Institute of MIT and Harvard
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.
CONDITIONS
Official Title
Germline Testing for Predisposition to Myeloid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age of 18 years or older
- Histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening
- Ability to understand and provide a signed and completed consent document in English
You will not qualify if you...
- Unable to safely undergo clinically indicated skin biopsy as determined by the study team
- Previous germline genetic testing for predisposition to myeloid malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
C
Christopher R Reilly, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here